Why the study?
Does aspirin 300 mg or 1200 mg daily alter coagulation, fibrinolytic, and platelet function compared to placebo in patients with transient ischaemic attacks?
Does aspirin 300 mg or 1200 mg daily alter coagulation, fibrinolytic, and platelet function compared to placebo in patients with transient ischaemic attacks?
Aspirin 300 mg and 1200 mg daily provide equivalent platelet inhibition, but the 1200 mg dose is associated with greater gastrointestinal blood loss.
Answers are grounded in this paper and cite their sources.
300 mg aspirin matches 1200 mg for platelet inhibition with less blood loss; supports lower-dose preference in TIA practice and trials.
Aspirin has been shown to be beneficial in the prophylaxis of arterial thromboembolic disease. The rationale for its use as an antithrombotic drug lies in its inhibition of thromboxane A2-dependent platelet function. However, the effect of aspirin on coagulation and fibrinolysis during chronic therapy has not been studied. We have measured a range of haemostatic and platelet functions in 49 patients with transient ischaemic attacks randomly allocated to aspirin 300 mg a day, aspirin 1,200 mg a day or placebo. All had been taking their allocated treatment for between 9 months and 4 years prior to investigation. Bleeding time was prolonged, serum thromboxane diminished and platelet aggregation to arachidonic acid but not ADP was abolished by both 300 mg and 1,200 mg aspirin, in a non-dose dependent fashion. Serum salicylate increased with the dose of aspirin ingested. No effect was seen with either dose of aspirin on urinary thromboxane and 6-keto-PGF1 alpha excretion, or on coagulation. Patients taking 1,200 mg aspirin a day had a lower haemoglobin and packed cell volume, lower resting fibrinopeptide A concentration and lower basal plasminogen activator activity than those on placebo. Response to venous occlusion was normal in all groups. The results suggest 300 mg and 1,200 mg aspirin have an equivalent platelet inhibitory effect but 1,200 mg aspirin causes greater gastro-intestinal blood loss.
No takes yet. Share an insight, caveat, or question.
Hampton et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: